Insulet makes the Omnipod, a tubeless, wearable insulin pump that replaces daily injections for diabetics, like a smart patch that automates insulin delivery.
Money comes from selling Omnipod systems and pods through pharmacies and distributors; with a 71% gross margin and recurring pod purchases, it's a high-margin, repeat-revenue model.
Insulet's tubeless design and integrated algorithm create switching costs, but Medtronic and Tandem Diabetes are launching similar patch pumps, eroding its uniqueness.
Sell (sector percentile 26) — value B, growth A, profitability B+, momentum D-, revisions D-. Updated daily, sector-relative, identical for every user.
Key events, in time order
Q2 beat but full-year guidance cut, plus class action lawsuit, multiple headwinds
Another law firm joins reminder, deadline approaching
Institutional investor trims position during quarter, reflecting portfolio adjustment
第一季度调整后每股收益为1.42美元，同比增长约40%；调整后营业利润率扩大110个基点至17.5%。
None yet
None yet
The discussion is about Insulet Corp. ($PODD) being included in a list of stocks experiencing money flow, indicating potential investor interest or trading activity.
Main discussion
Where is money flowing today? $AMLX $HAE $TDTH $FOUR $TRGP $BBWI $DUOL $ULTA $GDDY $LULU $SPOT $CHWY $MNDY $VERX $BRZE $ASO $PODD $LBRDA $ERIE $LBRDK $GSHD $CHTR $APPN $MMS $TAK $MGNI $TPR $MNST $HUBS $INTU $PLMR $TYL $DASH $TMDX $AAP $INTA $LOPE $MTCH $OLLI $FDS https://www.hedg
Here are the current top 5 best and worst performing stocks in the S&P 500 so far in 2026 Best: 🥇 Sandisk $SNDK +653%🟢 🥈 $DELL +281%🟢 🥉 Seagate $STX +262%🟢 4 Micron $MU +257%🟢 5 Western Digital $WDC +208%🟢 Worst: 💩 Trade Desk $TTD -65%🔴 2 Applovin $APP -54%🔴 3 Costar $CSGP -54%🔴
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
